Cyclodextrin-based polymers for therapeutic delivery
OwnerThomas C. Crawford, Oliver S. Fetzer +2inventors
InventorsThomas C. Crawford, Oliver S. Fetzer, Lawrence Alan Reiter, Marc Wolfgang
Life of this patent
Estimating the term…
Abstract
Methods and compositions relating to CDP-taxane conjugates are described herein.
Claims55
A method of treating cancer in a subject, wherein the subject has cancer and has received an anticancer agent, the method comprising administering to the subject a CDP-taxane conjugate in an amount effective to treat the cancer, to thereby treat the cancer.
-3. (canceled)
-9. (canceled)
A method of identifying a subject for treatment with a CDP-taxane conjugate, the method comprising identifying a subject having cancer who has received an anticancer agent;
- and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of treating a chemotherapeutic sensitive, a chemotherapeutic refractory, a chemotherapeutic resistant, and/or a relapsed cancer in a subject, the method comprising administering a CDP-taxane conjugate to a subject in an amount effective to treat a chemotherapeutic sensitive, a chemotherapeutic refractory, a chemotherapeutic resistant, and/or a relapsed cancer, to thereby treat the chemotherapeutic sensitive, the chemotherapeutic refractory, the chemotherapeutic resistant, and/or the relapsed cancer.
-14. (canceled)
-20. (canceled)
A method of treating cancer in a subject, the method comprising administering a CDP-taxane conjugate, wherein the CDP-taxane conjugate is of the following formula:
- wherein each L is independently a linker or absent and each D is independently a taxane, a prodrug derivative thereof, or absent and wherein the group
- has a Mw of 3.4 kDa or less and n is at least 4, provided that the polymer comprises at least one taxane, to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
-25. (canceled)
A method of treating metastatic or locally advanced breast cancer in a subject, the method comprising providing a subject who has metastatic or locally advanced breast cancer and has been treated with a chemotherapeutic agent which did not effectively treat the cancer or which had an unacceptable side effect, and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
-36. (canceled)
A method of treating hormone refractory prostate cancer in a subject, the method comprising:
- providing a subject who has hormone refractory prostate cancer and has been treated with a chemotherapeutic agent that did not effectively treat the cancer or who had an unacceptable side effect, and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
-54. (canceled)
-131. (canceled)
A method of identifying a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising
- identifying a subject having cancer who has received an anticancer agent and has a neutrophil count less than a standard;
- and
- identifying the subject as suitable for treatment with a CDP-taxane conjugate.
-137. (canceled)
A method of treating a subject having cancer, the method comprising selecting a subject having cancer who has received an anticancer agent and has a neutrophil count less than a standard;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-141. (canceled)
A method for selecting a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising:
- determining whether a subject with a proliferative disorder has moderate to severe neutropenia;
- and
- selecting a subject for treatment with a CDP-taxane conjugate on the basis that the subject has moderate to severe neutropenia.
-146. (canceled)
A method for treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has moderate to severe neutropenia;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-151. (canceled)
A method for selecting a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising:
- determining whether a subject with cancer, has experienced neuropathy from treatment with an anticancer agent;
- and
- selecting a subject for treatment with a CDP-taxane conjugate, on the basis that the subject has experienced neuropathy from treatment with an anticancer agent.
-157. (canceled)
A method for treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has experienced one or more symptom of neuropathy from treatment with a anticancer agent;
- and
- administering a CDP-taxane conjugate, to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-179. (canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer has or is at risk of having hepatic impairment, e.g., determining alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin levels in a subject having cancer;
- and
- selecting a subject having hepatic impairment, e.g., a subject having ALT and/or AST levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than 2 times the ULN, for treatment with a CDP-taxane conjugate.
(canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has or is at risk of having hepatic impairment, e.g., a subject having alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than 2 times the ULN;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer has or is at risk of having hepatic impairment, e.g., determining alkaline phosphatase (ALP), serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and/or bilirubin levels in the subject having cancer;
- and
- selecting a subject having or at risk of having hepatic impairment, e.g., a subject having ALP levels greater than 2.5 times the upper limit of normal (ULN), SGOT and/or SGPT levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than the ULN for treatment with a CDP-taxane conjugate.
(canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has or is at risk of having hepatic impairment, e.g., a subject having alkaline phosphatase (ALP) levels greater than 2.5 times the upper limit of normal (ULN), serum glutamate oxaloacetate transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) levels greater than 1.5 times the ULN and/or bilirubin levels greater than the ULN;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer is currently being administered or will be administered a cytochrome P450 isoenzyme and/or a CYP2C8 inhibitor;
- and
- selecting a subject with cancer who is currently being administered or will be administered a cytochrome P450 isoenzyme and/or a CYP2C8 inhibitor, for treatment with a CDP-taxane conjugate.
-191. (canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject having cancer who is currently being administered or will be, administered a cytochrome P450 isoenzyme, and/or a CYP2C8 inhibitor;
- and
- administering a CDP-taxane conjugate to the subject at a dose described herein, to thereby treat the cancer
-197. (canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject with cancer is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent, and
- selecting a subject who is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent for treatment with a CDP-taxane conjugate.
(canceled)
A CDP-taxane conjugate of the following formula:
- wherein each L is independently a linker or absent and each D is independently a taxane, a prodrug derivative thereof, or absent and wherein the group
- has a Mw of 3.4 kDa or less and n is at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, provided that the polymer comprises at least one taxane.
(canceled)
-204. (canceled)
(canceled)
Dependencies are inferred from the claim text.